Kcne2 Antibody

What is KCNE2 and why is it significant in scientific research?

KCNE2 (potassium voltage-gated channel subfamily E member 2) is a regulatory subunit that modifies the function of several potassium channels, most notably KCNQ1 and hERG. KCNE2 significantly slows KCNQ1 deactivation, shifts its voltage dependence of activation leftward, and decreases current density. Uniquely, KCNE2 enables KCNQ1 to be activated by low extracellular pH, whereas KCNQ1 alone is inhibited by external protons .

KCNE2 research is critical because:

• It plays essential roles in gastric acid secretion in parietal cells

• It has implications in gastric cancer development

• It contributes to cerebrospinal fluid composition regulation

• KCNE2 mutations are associated with cardiac arrhythmias including Long QT syndrome

What applications are KCNE2 antibodies validated for?

Based on current commercial antibodies, KCNE2 antibodies are primarily validated for Western blot (WB) applications . While immunohistochemistry has been used in research settings to detect KCNE2 in tissues such as choroid plexus epithelium, commercial antibodies may not explicitly list this as a validated application . Most published research uses Western blotting as the primary method for KCNE2 detection and quantification.

What is the expected molecular weight of KCNE2 in experimental applications?

KCNE2 has a calculated molecular weight of approximately 14-15 kDa. Specifically:

• Calculated MW: 14 kDa

• Observed MW on Western blots: 15 kDa

This slight discrepancy between calculated and observed weights is common for membrane proteins and may reflect post-translational modifications or the highly hydrophobic nature of the protein. When running Western blots, researchers should expect to see bands at approximately 15 kDa, though additional bands at higher molecular weights might represent glycosylated forms or multimers.

What are the recommended storage conditions for KCNE2 antibodies?

For optimal antibody performance and longevity, KCNE2 antibodies should be:

• Stored at -20°C for long-term storage (up to one year)

• Kept at 4°C for short-term storage and frequent use (up to one month)

• Aliquoted before freezing to avoid repeated freeze-thaw cycles

• Prepared in buffer containing stabilizers (typically PBS with 50% glycerol and 0.02% sodium azide)

Proper storage ensures antibody stability and consistent experimental results. Repeated freeze-thaw cycles should be avoided as they can lead to antibody degradation and reduced sensitivity.

What dilutions should I use for KCNE2 antibodies in Western blotting?

• The specific antibody formulation

• Sample type and protein concentration

• Detection method (chemiluminescence, fluorescence, etc.)

• Signal-to-noise ratio requirements

It is always advisable to perform a dilution series in initial experiments to determine the optimal concentration for your specific experimental conditions. Begin with the manufacturer's recommended range and adjust as needed based on signal intensity and background levels.

How can I validate the specificity of a KCNE2 antibody?

Validating antibody specificity is crucial for reliable results. For KCNE2 antibodies, consider these approaches:

• Positive controls: Use tissues known to express high levels of KCNE2 (e.g., gastric parietal cells, choroid plexus epithelium)

• Negative controls:

  • Tissues from Kcne2-/- knockout mice (gold standard)

  • Tissues known not to express KCNE2

  • Secondary antibody-only controls

• Peptide competition assay: Pre-incubate the antibody with the immunogen peptide before application to samples. This should eliminate specific binding.

• siRNA knockdown: Verify reduced signal in cells where KCNE2 has been knocked down by siRNA

• Overexpression systems: Confirm increased signal in cells overexpressing KCNE2

The most definitive validation comes from Kcne2-/- knockout tissue, which has been successfully used to confirm antibody specificity in previous studies .

What tissues are optimal for studying KCNE2 expression?

Based on research findings, the following tissues show significant KCNE2 expression and are suitable for antibody validation and experimental studies:

When selecting tissues for positive controls, choroid plexus and gastric tissue are particularly useful due to their high expression levels and the availability of Kcne2-/- tissues as negative controls.

How can I detect KCNE2 in protein complexes with channel partners?

KCNE2 functions through interactions with various potassium channels and transporters. To study these complexes:

• Co-immunoprecipitation (Co-IP):

  • Use anti-KCNE2 antibodies to pull down complex proteins

  • Verify interactions by immunoblotting for partners (KCNQ1, hERG, SMIT1)

  • Optimize lysis conditions to preserve membrane protein interactions

  • Use crosslinking agents if interactions are weak or transient

• Proximity Ligation Assay (PLA):

  • Allows in situ detection of protein-protein interactions

  • Requires antibodies against both interaction partners from different species

  • Signals appear as fluorescent dots when proteins are in close proximity (<40nm)

• Blue Native PAGE:

  • Separates intact protein complexes while maintaining native state

  • Follow with Western blotting to identify complex components

Research has successfully used these approaches to identify novel complexes including KCNE2-KCNQ1-SMIT1, revealing unexpected functional relationships between channels and transporters .

What are the challenges in detecting KCNE2 in neuronal populations?

While KCNE2 is reportedly expressed in neuronal populations (based on in situ hybridization), detection at the protein level has proven challenging. Studies report difficulty detecting KCNE2 protein in mouse neurons by immunohistochemistry despite clear detection in choroid plexus epithelium .

Potential strategies to overcome these challenges include:

• Signal amplification methods:

  • Tyramide signal amplification (TSA)

  • Enhanced chemiluminescence systems for Western blots

• Sample enrichment:

  • Membrane fraction isolation

  • Immunoprecipitation prior to detection

• Alternative detection methods:

  • RNA-level analysis (qPCR, in situ hybridization)

  • Mass spectrometry for protein identification

• Higher sensitivity antibodies:

  • Monoclonal antibodies targeting specific epitopes

  • Higher affinity antibodies for low-abundance detection

The difficulty in neuronal detection may represent a true biological difference in expression levels or could reflect technical limitations in current antibody sensitivity.

How can I use KCNE2 antibodies to study disease-associated changes in expression?

KCNE2 expression changes have been documented in several pathological conditions, particularly in gastric cancer. To study these changes:

• Comparative expression analysis:

  • Compare normal versus pathological tissues using Western blot quantification

  • Use immunohistochemistry to assess localization changes in disease states

• Cancer progression studies:

  • Analyze KCNE2 expression across different stages of gastric cancer

  • Correlate with markers of cell cycle regulation (e.g., cyclin D1)

• Experimental models:

  • Use Kcne2-/- mice as models for gastric pathology

  • Study gastritis cystica profunda development (8-fold increase in stomach mass by one year of age)

  • Monitor progression from hyperplasia to metaplasia and neoplasia

• Mechanistic studies:

  • Evaluate nuclear cyclin D1 localization in relation to KCNE2 expression

  • Investigate direct influences on cell cycle regulation independent of channel function

Research has shown that KCNE2 expression is disrupted and reduced in human gastric carcinoma and adenocarcinoma, and similar findings have been observed in areas of cysts in human patients with gastric adenocarcinoma .

What techniques can be used to study KCNE2 interactions with transporters like SMIT1?

The discovery of KCNE2-KCNQ1-SMIT1 complexes represents an important advance in understanding how channels and transporters can functionally interact. To study these novel complexes:

• Functional co-expression studies:

  • Measure myo-inositol transport in the presence/absence of KCNE2

  • Use electrophysiology to measure currents in conjunction with transport assays

• FRET/BRET analysis:

  • Tag KCNE2 and transport partners with fluorescent/bioluminescent proteins

  • Measure energy transfer as indicator of protein proximity

• Mutational analysis:

  • Create point mutations in KCNE2 to disrupt specific interactions

  • Identify critical residues for functional coupling

• In vivo correlation studies:

  • Measure CSF myo-inositol levels in Kcne2-/- mice

  • Correlate with seizure susceptibility and other phenotypes

Research has found that Kcne2 knockout mice show reduced CSF myo-inositol levels and increased seizure susceptibility, suggesting functional consequences of disrupting these channel-transporter complexes .

What are common pitfalls when using KCNE2 antibodies and how can they be addressed?

Several challenges may arise when working with KCNE2 antibodies:

• Low signal intensity:

  • Reduce antibody dilution (try 1:500 instead of 1:2000)

  • Increase protein loading on Western blots

  • Extend primary antibody incubation time (overnight at 4°C)

  • Use more sensitive detection systems

• High background:

  • Increase blocking time or concentration

  • Add 0.1-0.3% Tween-20 to washing buffers

  • Increase washing duration and number of washes

  • Use higher dilution of secondary antibody

• Non-specific bands:

  • Validate with positive and negative controls

  • Use gradient gels for better separation

  • Consider using monoclonal antibodies for higher specificity

• Poor reproducibility:

  • Maintain consistent experimental conditions

  • Aliquot antibodies to avoid freeze-thaw cycles

  • Use internal loading controls for normalization

Carefully optimizing each step of your protocol based on these considerations can significantly improve results with KCNE2 antibodies.

How can I optimize immunofluorescence protocols for KCNE2 detection?

While commercial KCNE2 antibodies may not explicitly list immunofluorescence as a validated application, many research laboratories have successfully used them for this purpose. To optimize immunofluorescence protocols:

• Fixation optimization:

  • Try both 4% paraformaldehyde and methanol fixation

  • For membrane proteins like KCNE2, gentle fixation conditions may better preserve epitopes

• Antigen retrieval:

  • Test heat-induced epitope retrieval (citrate buffer pH 6.0)

  • Try enzymatic retrieval with proteinase K

• Permeabilization:

  • Use 0.1-0.3% Triton X-100 for adequate membrane permeabilization

  • Consider saponin (0.1%) for milder permeabilization

• Signal enhancement:

  • Use tyramide signal amplification

  • Consider biotin-streptavidin amplification systems

• Controls and co-localization:

  • Use membrane markers to confirm appropriate localization

  • Counterstain with DAPI to visualize nuclei

  • Include Kcne2-/- tissue as negative control

Successful immunofluorescence has been reported for KCNE2 in choroid plexus epithelium, demonstrating apical localization facing the CSF .

How might KCNE2 antibodies contribute to understanding its role in novel physiological contexts?

KCNE2 research continues to reveal unexpected functions beyond its classical roles in cardiac and gastric physiology. Future antibody-based research could explore:

• KCNE2 in metabolic regulation:

  • Investigate potential roles in pancreatic beta cells or adipose tissue

  • Study interactions with metabolite transporters in various tissues

• Neurological functions:

  • Further explore the relationship between CSF myo-inositol levels and seizure susceptibility

  • Investigate potential roles in neuronal excitability beyond the choroid plexus

• Cancer biology beyond gastric cancer:

  • Examine expression in other epithelial cancers

  • Investigate direct effects on cell cycle regulation

  • Study potential as a diagnostic or prognostic marker

• Developmental biology:

  • Track expression patterns during embryonic and postnatal development

  • Investigate potential roles in tissue differentiation and organogenesis

As research tools improve, antibodies with enhanced sensitivity may reveal KCNE2 expression in previously undetected cell types, potentially uncovering novel physiological roles.